Cargando…
The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
There are many treatments for metastatic colorectal cancer (mCRC). Among them, uncertainty remains especially concerning the clinical benefit of different regimens for left-sided RAS wild-type (WT) mCRC in the triple-drug therapy era. No studies have been conducted to answer this critical clinical i...
Autores principales: | Cai, Changjing, Luo, Qingqing, Liu, Yihan, Peng, Yinghui, Zhang, Xiangyang, Jiang, Zhaohui, Feng, Ziyang, Qi, Yaru, Gao, Yan, Liu, Yongting, Liu, Ping, Chen, Yihong, Guo, Cao, Shen, Hong, Zeng, Shan, Han, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561342/ https://www.ncbi.nlm.nih.gov/pubmed/36249804 http://dx.doi.org/10.3389/fphar.2022.1015510 |
Ejemplares similares
-
Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens
por: Arikan, Rukiye, et al.
Publicado: (2023) -
A Multi-Omics Analysis of NASH-Related Prognostic Biomarkers Associated with Drug Sensitivity and Immune Infiltration in Hepatocellular Carcinoma
por: Liu, Yongting, et al.
Publicado: (2023) -
A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers
por: Chen, Yihong, et al.
Publicado: (2023) -
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
por: Parisi, Alessandro, et al.
Publicado: (2021) -
Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)